Cerebrospinal fluid metagenomic next-generation sequencing for culture-negative anaerobic central nervous system infection involving Prevotella oris: attribution challenges in low-biomass specimens
- 1Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, China
- 2Division of Colorectal Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, China
- 3Yuncheng Central Hospital affiliated to Shanxi Medical University, Yuncheng, China
Abstract
Anaerobic central nervous system (CNS) infections are uncommon but diagnostically difficult because fastidious organisms may be suppressed by empirical antimicrobial therapy and conventional cultures may remain negative. Cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) can recover microbial nucleic acids in this setting, but low microbial biomass creates a central attribution problem: a detected organism may represent active infection, introduced commensal DNA, laboratory background, or bioinformatic misclassification. This narrative Mini Review uses Prevotella oris as a representative oral anaerobe to examine that problem. We synthesize evidence on low-biomass CSF specimen processing and sequencing strategies, including nanopore sequencing, whole-genome amplification, and targeted approaches, alongside contamination control, sequence-level and taxonomic credibility, host-response immunology, neuroimaging and source concordance, antimicrobial timing, and discordant clinical scenarios. We then organize these established principles into an expert-informed two-step pathway that separates technical signal credibility from clinical attribution and explicitly preserves an indeterminate state when evidence conflicts. P. oris is positioned as a useful model of the plausible contaminant paradox rather than as a pathogen with a unique CNS phenotype. We also outline syndrome-based management, source control, and treatment-duration principles. The framework is conceptual and non-validated; its purpose is transparent reasoning and reporting, not diagnostic scoring or probability estimation.
Related
- High-throughput screening for central nervous system infection-associated pathogens using TaqMan array cards, metagenomic next-generation sequencing, and targeted next-generation sequencing: a retrospective study
- Metagenomic next-generation sequencing of aqueous humor guides targeted therapy for Staphylococcus epidermidis endophthalmitis in chronic ocular graft-versus-host disease: a case report
- Metagenomic next-generation sequencing improves pathogen detection in culture-negative infections: a diagnostic performance study
- Analysis of structural modifications and metagenomic sequencing during the ensiling of Caragana korshinskii provides insights into how extrusion pretreatment promotes lignocellulose degradation
- Advancing Neurological Liquid Biopsy via Six-Base Sequencing of Cerebrospinal Fluid Cell-Free DNA
BibTeX
@article{li2026cerebrospinal,
title = {{Cerebrospinal fluid metagenomic next-generation sequencing for culture-negative anaerobic central nervous system infection involving Prevotella oris: attribution challenges in low-biomass specimens}},
author = {Yan Li and Minghua Fan and Yuyuan Hu and Yuhang Yang and Wenyuan Li and Wei Zhang and Yanhong Wang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1896093},
url = {https://doi.org/10.3389/fimmu.2026.1896093},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cerebrospinal fluid metagenomic next-generation sequencing for culture-negative anaerobic central nervous system infection involving Prevotella oris: attribution challenges in low-biomass specimens
AU - Yan Li
AU - Minghua Fan
AU - Yuyuan Hu
AU - Yuhang Yang
AU - Wenyuan Li
AU - Wei Zhang
AU - Yanhong Wang
PY - 2026
DA - 2026/10/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1896093
UR - https://doi.org/10.3389/fimmu.2026.1896093
AB - Anaerobic central nervous system (CNS) infections are uncommon but diagnostically difficult because fastidious organisms may be suppressed by empirical antimicrobial therapy and conventional cultures may remain negative. Cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) can recover microbial nucleic acids in this setting, but low microbial biomass creates a central attribution problem: a detected organism may represent active infection, introduced commensal DNA, laboratory background, or bioinformatic misclassification. This narrative Mini Review uses Prevotella oris as a representative oral anaerobe to examine that problem. We synthesize evidence on low-biomass CSF specimen processing and sequencing strategies, including nanopore sequencing, whole-genome amplification, and targeted approaches, alongside contamination control, sequence-level and taxonomic credibility, host-response immunology, neuroimaging and source concordance, antimicrobial timing, and discordant clinical scenarios. We then organize these established principles into an expert-informed two-step pathway that separates technical signal credibility from clinical attribution and explicitly preserves an indeterminate state when evidence conflicts. P. oris is positioned as a useful model of the plausible contaminant paradox rather than as a pathogen with a unique CNS phenotype. We also outline syndrome-based management, source control, and treatment-duration principles. The framework is conceptual and non-validated; its purpose is transparent reasoning and reporting, not diagnostic scoring or probability estimation.
SN - 1664-3224
ER -